OM · Company research
Outset Medical, Inc. Common Stock (OM): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
28records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| NIBE Industrier (OM:NIBE B) Stock Looks Near Fair Value As Cash Flow Comes Into Focus - Yahoo Finance | NIBE Industrier (OM:NIBE B) Stock Looks Near Fair Value As Cash Flow Comes Into Focus Yahoo Finance | View source ↗ | Yahoo Finance | Oct 19, 2026 | neutral | 0 | 0.6 |
| Lindab (OM:LIAB) Stock Looks Undervalued Following a 41% Five Year Fall - Yahoo Finance | Lindab (OM:LIAB) Stock Looks Undervalued Following a 41% Five Year Fall Yahoo Finance | View source ↗ | Yahoo Finance | Oct 19, 2026 | neutral | 0 | 0.6 |
| What Cloetta (OM:CLA B) Stock Value Review Means For Shareholders - Simply Wall Street | What Cloetta (OM:CLA B) Stock Value Review Means For Shareholders Simply Wall Street | View source ↗ | Simply Wall Street | Oct 18, 2026 | neutral | 0 | 0.6 |
| Getinge (OM:GETI B) Stock May Trade At A 37% Discount On Cash Flow - Yahoo Finance | Getinge (OM:GETI B) Stock May Trade At A 37% Discount On Cash Flow Yahoo Finance | View source ↗ | Yahoo Finance | Oct 18, 2026 | neutral | 0 | 0.6 |
| Lagercrantz Group (OM:LAGR B) Stock Looks Fully Priced Following Its 135% Run - Yahoo Finance | Lagercrantz Group (OM:LAGR B) Stock Looks Fully Priced Following Its 135% Run Yahoo Finance | View source ↗ | Yahoo Finance | Oct 18, 2026 | neutral | 0 | 0.6 |
| Thule Group (OM:THULE) Stock May Be 49% Undervalued On Cash Flow - Yahoo Finance | Thule Group (OM:THULE) Stock May Be 49% Undervalued On Cash Flow Yahoo Finance | View source ↗ | Yahoo Finance | Oct 18, 2026 | neutral | 0 | 0.6 |
| AddLife (OM:ALIF B) Stock May Be 18% Undervalued On Cash Flow - Yahoo Finance | AddLife (OM:ALIF B) Stock May Be 18% Undervalued On Cash Flow Yahoo Finance | View source ↗ | Yahoo Finance | Oct 18, 2026 | neutral | 0 | 0.6 |
| BioGaia (OM:BIOG B) Stock Looks Undervalued With 29% Upside To Fair Value - Yahoo Finance | BioGaia (OM:BIOG B) Stock Looks Undervalued With 29% Upside To Fair Value Yahoo Finance | View source ↗ | Yahoo Finance | Oct 18, 2026 | neutral | 0 | 0.6 |
| NP3 Fastigheter (OM:NP3) Stock Stalls As Q3 Earnings Face Rate Pressure - Yahoo Finance | NP3 Fastigheter (OM:NP3) Stock Stalls As Q3 Earnings Face Rate Pressure Yahoo Finance | View source ↗ | Yahoo Finance | Oct 18, 2026 | neutral | 0 | 0.6 |
| Beijer Alma (OM:BEIA B) Stock May Be 27% Undervalued On Cash Flow - Yahoo Finance | Beijer Alma (OM:BEIA B) Stock May Be 27% Undervalued On Cash Flow Yahoo Finance | View source ↗ | Yahoo Finance | Oct 18, 2026 | neutral | 0 | 0.6 |
| Teqnion (OM:TEQ) Stock Price Meets Q3 Earnings With Margin Doubts - Yahoo Finance | Teqnion (OM:TEQ) Stock Price Meets Q3 Earnings With Margin Doubts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 18, 2026 | neutral | 0 | 0.6 |
| Electrolux (OM:ELUX B) Stock Looks Reasonable Despite A 73% Slide - Yahoo Finance | Electrolux (OM:ELUX B) Stock Looks Reasonable Despite A 73% Slide Yahoo Finance | View source ↗ | Yahoo Finance | Oct 17, 2026 | neutral | 0 | 0.6 |
| Attendo (OM:ATT) Opens New Finnish Care Home, Is The Stock Still Cheap? - Yahoo Finance | Attendo (OM:ATT) Opens New Finnish Care Home, Is The Stock Still Cheap? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 12, 2026 | neutral | 0 | 0.6 |
| Trelleborg (OM:TREL B) Stock May Be 28% Undervalued On Cash Flow - Yahoo Finance | Trelleborg (OM:TREL B) Stock May Be 28% Undervalued On Cash Flow Yahoo Finance | View source ↗ | Yahoo Finance | Oct 10, 2026 | neutral | 0 | 0.6 |
| Boliden (OM:BOL) Nears Its Q3 Report, Is The Stock Fully Valued? - Yahoo Finance | Boliden (OM:BOL) Nears Its Q3 Report, Is The Stock Fully Valued? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 10, 2026 | neutral | 0 | 0.6 |
| Elekta (OM:EKTA B) Unveils New ASTRO Data, Is The Stock Still Below Fair Value? - Yahoo Finance | Elekta (OM:EKTA B) Unveils New ASTRO Data, Is The Stock Still Below Fair Value? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 10, 2026 | neutral | 0 | 0.6 |
| Sandvik (OM:SAND) Stock May Be 11% Undervalued On Cash Flow - Yahoo Finance | Sandvik (OM:SAND) Stock May Be 11% Undervalued On Cash Flow Yahoo Finance | View source ↗ | Yahoo Finance | Oct 10, 2026 | neutral | 0 | 0.6 |
| Wihlborgs Fastigheter (OM:WIHL) Stock Trades At A Discount To Fair Value - Yahoo Finance | Wihlborgs Fastigheter (OM:WIHL) Stock Trades At A Discount To Fair Value Yahoo Finance | View source ↗ | Yahoo Finance | Oct 10, 2026 | neutral | 0 | 0.6 |
| Implantica (OM:IMP A SDB) Draws Strong US Interest, Is The Stock Still Cheap? - Yahoo Finance | Implantica (OM:IMP A SDB) Draws Strong US Interest, Is The Stock Still Cheap? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 10, 2026 | neutral | 0 | 0.6 |
| Skanska (OM:SKA B) Stock Looks Reasonable After A 72% Three Year Run - Yahoo Finance | Skanska (OM:SKA B) Stock Looks Reasonable After A 72% Three Year Run Yahoo Finance | View source ↗ | Yahoo Finance | Oct 10, 2026 | neutral | 0 | 0.6 |
| Boliden (OM:BOL) Stock Sees Split Analyst Revisions As Fair Value Edges Higher - Yahoo Finance | Boliden (OM:BOL) Stock Sees Split Analyst Revisions As Fair Value Edges Higher Yahoo Finance | View source ↗ | Yahoo Finance | Oct 9, 2026 | neutral | 0 | 0.6 |
| BioArctic (OM:BIOA B) Stock May Be Fully Priced On Sales Growth Hopes - Yahoo Finance | BioArctic (OM:BIOA B) Stock May Be Fully Priced On Sales Growth Hopes Yahoo Finance | View source ↗ | Yahoo Finance | Oct 9, 2026 | neutral | 0 | 0.6 |
| Boliden (OM:BOL) Stock May Be 49% Undervalued As Cash Flow Risks Linger - Yahoo Finance | Boliden (OM:BOL) Stock May Be 49% Undervalued As Cash Flow Risks Linger Yahoo Finance | View source ↗ | Yahoo Finance | Oct 9, 2026 | neutral | 0 | 0.6 |
| Here's Why You Should Retain DaVita Stock in Your Portfolio for Now | DaVita (DVA) has rallied 55.8% year-to-date, driven by strong Integrated Kidney Care (IKC) platform growth, improving treatment volumes, and technology investments. The company beat Q2 expectations by $40 million in adjusted operating income and raised full-year guidance. However, persistent headwinds include declining revenue per treatment due to commercial-mix pressure (estimated $70 million impact in 2027), elevated G&A costs limiting operating leverage, and limited acquisition opportunities in a consolidated market. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.25 | 1 |
| Here's Why You Should Retain DaVita Stock in Your Portfolio for Now | DaVita (DVA) has rallied 55.8% year-to-date, driven by strong Integrated Kidney Care (IKC) platform growth, improving treatment volumes, and technology investments. The company beat Q2 expectations by $40 million in adjusted operating income and raised full-year guidance. However, persistent headwinds include declining revenue per treatment due to commercial-mix pressure (estimated $70 million impact in 2027), elevated G&A costs limiting operating leverage, and limited acquisition opportunities in a consolidated market. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.25 | 1 |
| SKF (OM:SKF B) Stock May Trade At A Discount After 54% Run - Yahoo Finance | SKF (OM:SKF B) Stock May Trade At A Discount After 54% Run Yahoo Finance | View source ↗ | Yahoo Finance | Oct 9, 2026 | neutral | 0 | 0.6 |
| Reasons to Retain Hims & Hers Stock in Your Portfolio for Now | Hims & Hers (HIMS) is accelerating growth through weight loss offerings, international expansion, and AI-enabled care, with U.S. revenues up 16% and international revenues surging 17-fold. However, the company faces headwinds from gross margin compression due to lower-margin branded products, negative cash flow from working capital requirements, and regulatory uncertainty around FDA peptide therapy approvals. The stock has gained 49.5% in six months but carries a Zacks Rank #3 (Hold) rating. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.25 | 1 |
| Reasons to Retain Hims & Hers Stock in Your Portfolio for Now | Hims & Hers (HIMS) is accelerating growth through weight loss offerings, international expansion, and AI-enabled care, with U.S. revenues up 16% and international revenues surging 17-fold. However, the company faces headwinds from gross margin compression due to lower-margin branded products, negative cash flow from working capital requirements, and regulatory uncertainty around FDA peptide therapy approvals. The stock has gained 49.5% in six months but carries a Zacks Rank #3 (Hold) rating. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.25 | 1 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.